Market Tracker

03/29 4:48pm ET

BioCryst Pharmaceuticals Inc (NASDAQ:BCRX)

8.49
Delayed Data
As of Mar 29
 -0.10 / -1.16%
Today’s Change
2.48
Today|||52-Week Range
9.25
+34.12%
Year-to-Date
Teva Launches Authorized Generic of Allergan's Minastrin
Mar 17 / Zacks.com - Paid Partner Content
Conatus Pharma (CNAT) Incurs Wider-than-Expected Loss in Q4
Mar 16 / Zacks.com - Paid Partner Content
Jazz Initiates Phase III Study for Narcolepsy Candidate
Mar 16 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close8.59
Today’s open8.59
Day’s range8.48 - 8.70
Volume745,647
Average volume (3 months)1,460,647
Market cap$681.3M
Dividend yield--
Data as of 3:59pm ET, 03/29/2017

Growth & Valuation

Earnings growth (last year)-27.12%
Earnings growth (this year)+12.93%
Earnings growth (next 5 years)+24.73%
Revenue growth (last year)-45.39%
P/E ratioNM
Price/Sales17.70
Price/Book401.59

Competitors

 Today’s
change
Today’s
% change
MYOVMyovant Sciences Ltd+0.26+2.29%
RTRXRetrophin Inc+0.50+2.83%
NDRMNeuroderm Ltd-0.20-0.74%
AMAGAMAG Pharmaceuticals...+0.60+2.70%
Data as of 4:02pm ET, 03/29/2017

Financials

Next reporting dateMay 10, 2017
EPS forecast (this quarter)-$0.18
Annual revenue (last year)$26.4M
Annual profit (last year)-$55.1M
Net profit margin-209.25%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Jon P. Stonehouse
Vice President-Investor Relations &
Operations
Robert Bennett
Corporate headquarters
Durham, North Carolina

Forecasts